ISRGHealthcare · Medical Instruments & SuppliesThe 34 Wall Street analysts covering Intuitive Surgical, Inc. hold a median 12-month price target of $484 — +15.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Intuitive Surgical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Accruals (40): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ISRG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.2% from it.
Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $485 |
| 8 Sept 2026 | BTIG | Reiterates | Buy | — |
| 8 Sept 2026 | BTIG | Reiterates | Buy | $469 |
| 12 Aug 2026 | Oppenheimer | Upgrade | Outperform | $500 |
| 12 Aug 2026 | Oppenheimer | Upgrade | Outperform | — |
| 30 July 2026 | HSBC | Downgrade | Hold | $931 |
| 30 July 2026 | HSBC | Downgrade | Hold | — |
| 28 July 2026 | UBS | Assumes | Buy | $550 → $500 |
| 17 July 2026 | Baird | Maintains | Outperform | — |
| 17 July 2026 | Baird | Maintains | Outperform | $525 → $500 |
| 17 July 2026 | Bernstein | Maintains | Outperform | $750 → $685 |
| 17 July 2026 | Bernstein | Maintains | Outperform | — |
| 17 July 2026 | BTIG | Maintains | Buy | — |
| 17 July 2026 | BTIG | Maintains | Buy | $512 → $469 |
| 17 July 2026 | Citigroup | Maintains | Buy | $590 → $500 |
| 17 July 2026 | Citigroup | Maintains | Buy | — |
| 17 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 17 July 2026 | Evercore ISI Group | Maintains | In-Line | $430 → $375 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | $550 → $450 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ISRG appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Intuitive Surgical, Inc. returned −3.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 11% of US stocks
Cheaper than 11% of US stocks
Cheaper than 7% of US stocks
Higher than 67% of US stocks
Higher than 62% of US stocks
Higher than 81% of US stocks
Higher than 89% of US stocks
Higher than 88% of US stocks
Higher than 78% of US stocks
Higher than 93% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Intuitive Surgical, Inc. has a market value of $149.1B and an enterprise value of $146.0B.
Revenue in the twelve months to 30 June 2026: $11.0B. The latest quarter grew 18.5% year on year.
Net income over the same four quarters: $3.2B, a 28.6% net margin.
Diluted earnings per share, trailing twelve months: $8.73.
Free cash flow in the twelve months to 30 June 2026: $3.2B, after $483.8M of capital spending.
Intuitive Surgical, Inc. spent $3.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 48.4×; forward P/E: 34.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Intuitive Surgical, Inc. employs 17,021 people — $648K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Intuitive Surgical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Intuitive Surgical shares rose nearly 12% over a month ahead of Q3 earnings. The excerpt cites da Vinci 5 adoption and Ion growth as momentum drivers, while noting valuation and other risks.
Why it matters — ISRG watchers may track how adoption and Ion growth factor into the company’s momentum alongside the stated valuation and risk concerns.
Intuitive Surgical has submitted a next-generation robotic endoscope to the FDA as it targets gastrointestinal care beyond surgery.
Why it matters — The submission highlights a potential new avenue for ISRG in GI care beyond its surgical focus.
Zacks upgraded Intuitive Surgical to Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — ISRG watchers may note the improved earnings outlook reflected in Zacks' upgrade and its stated potential near-term effect on the stock.
Zacks Investment Research highlights Intuitive Surgical, along with Chipotle and BP, for strong sales growth, solid cash flow and favorable valuation metrics as Q3 earnings begin.
Why it matters — The item places ISRG among companies noted for these financial characteristics at the start of the Q3 earnings season.
Zacks Investment Research reports that Intuitive Surgical has recently been among the stocks most watched by Zacks.com users. The item says it is worth exploring what may lie ahead for the stock.
Why it matters — ISRG watchers may be interested in the recent attention the stock is receiving and the article’s discussion of its outlook.
The 34 Wall Street analysts covering Intuitive Surgical, Inc. have a median 12-month price target of $484, with estimates ranging from $324 to $685. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 34 analysts covering Intuitive Surgical, Inc., 26 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Intuitive Surgical, Inc. 74 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Intuitive Surgical, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 34 analysts implies +15.2% from the last close, and Ticker Nerd's factor model ranks Intuitive Surgical, Inc. 74 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intuitive Surgical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISRG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $324 to $685 over the next 12 months.
Intuitive Surgical, Inc. returned -3.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "ISRG Gains Nearly 12% in a Month: Should You Buy, Hold or Sell?". Intuitive Surgical shares rose nearly 12% over a month ahead of Q3 earnings. The excerpt cites da Vinci 5 adoption and Ion growth as momentum drivers, while noting valuation and other risks.
Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care. Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems, which are used by surgeons to perform procedures with enhanced precision through a minimally invasive approach. The company also offers the Ion endoluminal system, extending its platform into diagnostic endoluminal procedures and lung biopsy applications. In addition to its core systems, Intuitive Surgical supports hospitals and healthcare providers with instruments, accessories, and services that help integrate robotic surgery into clinical workflows. Its products serve a broad range of specialties, including general surgery, urology, gynecology, thoracic surgery, and diagnostic care. Headquartered in Sunnyvale, California, Intuitive Surgical plays a significant role in the global healthcare equipment market by advancing the adoption of robotic systems in modern surgical and diagnostic settings.
CEO Mr. David J. Rosa · 17,021 employees · United States · https://www.intuitive.com
